Both dupilumab and mepolizumab were originally approved for asthma but were subsequently studied in patients with COPD who continue to experience symptoms and moderate-to-severe exacerbations despite ...

This publication aims to improve treatment and care for adults with chronic obstructive pulmonary disease (COPD). It provides commissioners with strategies and recommendations for frontline care, ...

David Mannino is co-founder and chief medical officer of the COPD Foundation. He's an internal medicine doctor with a specialty in pulmonary, critical care, and sleep medicine at University of ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the world’s first low-carbon version of a triple-combination inhaler for chronic obstructive pulmonary disease (COPD). The ...

Early identification and treatment of patients with COPD at risk of exacerbation are crucial for better outcomes. Single-inhaler triple therapy (SITT) users showed improved exacerbation rates and ...

Every 30 seconds, someone in the world will experience a flare-up of their asthma or chronic obstructive pulmonary disease (COPD) symptoms. For decades, the standard treatment for these potentially ...

An injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further treatment by 30%. The findings, published in The ...

Verona Pharma, a clinical-stage biopharmaceutical company, is making strides with its novel COPD treatment, ensifentrine, exhibiting promise in addressing significant unmet needs in the COPD market.

This guidance provides strategies that optimise chronic obstructive pulmonary disease (COPD) care across the pathway and offer integrated care boards a consistent methodology and set of strategies for ...